HOWL Werewolf: Enterprise Value-to-Revenue Multiple

Public company logo of Werewolf Therapeutics Inc. (HOWL)

The minimal predictability of Werewolf Therapeutics cash flows due to its research stage is evident in the EV/Sales ratio trend, where the parameter has settled at 287.62. Business stability is based on the INDUKINE platform and partnerships with industry behemoths. The capitalization of HOWL currently depends on internal development cycles and the results of early trials of new cancer-fighting molecules.

Company Value to Revenue: Werewolf (HOWL) for 11/23/2025 - 11/20/2026

Werewolf - analytical breakdowns and key metrics (HOWL)

- share price and consensus valuation forecast:
Initial company analysis:Werewolf Therapeutics Inc. HOWL
Product sample of Werewolf Therapeutics Inc.

The EV/Sales ratio measures business value relative to annual revenue, excluding the impact of debt load to reveal the actual market valuation of assets. By analyzing the EV/Sales history, an investor sees the current value of 287.62, which, combined with the protected legal status of Werewolf Therapeutics (HOWL) biologics in the US, minimizes the risk of a "value trap" when determining consolidation boundaries.

Competitor analysis for Werewolf Therapeutics

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP